In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Body-based burial: Students imagine urns made from blood and hair
In Slovenia, students at University of Ljubljana have used biobased materials for a variety of design projects, including a biodegradable urn made of blood...
Uttar Pradesh eyes cow poop plastics to boost rural economy
In Uttar Pradesh, a government project is collecting cow dung to convert into usable products such as bioplastics, textiles, and paper.
The Press Trust...
Luxury brand Velvet Eyewear lauds advances in biobased acetate
In California, luxury women’s eyewear brand Velvet Eyewear has unveiled its first biobased eyewear collection.
Crafted from renewable sources like wood pulp and cotton...